Mice were inoculated intranasally with vesicular stomatitis virus 16 to 22 h after being exposed to smallparticle aerosols of saline, natural mouse alpha interferon, recombinant human alpha interferon A, or hybrid recombinant human alpha interferon A/D bgl for 2, 4, or 8 h. Compared with comparably inoculated, untreated mice, significantly reduced levels of vesicular stomatitis virus were observed in the lungs of animals treated with any interferon preparation for 8 h and in groups treated with mouse alpha interferon or hybrid recombinant human alpha interferon A/D bgl for 4 h. No significant reductions in lung virus titers were observed in any group treated with interferon for 2 h or in any of the groups treated with saline.
Many efforts have been made to use preparations of interferon or interferon inducers to treat experimentally induced respiratory virus infections (1-4, 8, 13, 14, 18, 19, 22) . The results of these tests have been inconsistent, but generally suggest that with improved methods of delivery and larger doses, interferons might be useful in the prophylaxis or treatment of respiratory viral infections. Recent advances in DNA recombinant technology have allowed the production of high-titered interferons in relatively large quantities (15) . We have been testing delivery of such interferons directly to the respiratory tract in small-particle aerosols. This method of delivery has been used with the antiviral agents amantadine and ribavirin to successfully treat experimental (9, 23, 24) and naturally acquired (6, 7, 10, 12, 20) influenza and respiratory syncytial virus infections. In a previous report, we described the deposition, respiratory clearance, and antiviral activity of small particles of interferons in the lungs of mice exposed to interferon aerosols continuously over a 4-day period (25). We have also reported that small-particle aerosols of recombinant interferons delivered 24 h a day for several days could protect cotton rats (Sigmodon hispidus) from vesicular stomatitis virus (VSV)-induced lung disease (C.-S. Sun, P. R. Wyde, S. Z. Wilson, and V. Knight resulting suspensions were centrifuged (100 x g) to remove cellular debris, portioned, and stored at -700C. The titer of this pool was 2 x 107 PFU/ml.
Infection of the animals. Mice were lightly anesthetized with ether and inoculated intranasally with 102 PFU of VSV in 0.05 ml. This dose was usually not lethal, but produced an asymptomatic disease that was not evident except for the growth of virus in infected lungs or by observing histopathological changes in hemotoxylin-and eosin-stained sections of lung tissue from infected animals.
Tissue cultures. Starting cultures of L929 cells were obtained from Flow Laboratories (McLean, Va.; no 03-439); Madin Darby bovine kidney (MDBK) cells were provided by the Department of Experimental and Applied Biology, Hoffman-La Roche, Inc., Nutley, N.J. Cell cultures of both lines were routinely passaged when confluent by using Eagle minimal essential medium supplemented with 2 mM Lglutamine, 100 U of penicillin per ml, 100 ,ug of streptomycin per ml, 0.2% sodium bicarbonate, and 10%o fetal calf serum.
Interferons. Both recombinant human alpha interferon A (rIFNaA) and hybrid recombinant human alpha interferon A/D bgl (rIFNaA/D) were obtained from the Department of Experimental and Applied Biology, Hoffmann-La Roche, Inc. The construction and specific molecular activities of these interferons have been described in detail previously (16 May (11) were used to generate continuous small-particle aerosols of interferon. The use of these generators to deliver other antiviral agents has been described previously (23, 24 (17) was used to compare GMTs from different groups. P values of cO.05 were considered statistically significant. RESULTS Effects of concentration. Table 1 compares titers of VSV in lungs of mice exposed for 4 h to small-particle aerosols of saline, MoIFN, rIFNcxA, or rIFNcxA/D and then challenged intranasally 20 h later with 100 PFU of VSV. The reservoir concentration of MoIFN used (5 x 103 U/ml) was the maximum concentration of this material that could be delivered practically. Groups of mice exposed to MoIFN or either concentration of rIFNotA/D had significantly lower pulmonary virus titers than comparably inoculated mice that were exposed to just saline (Table 1 ). In contrast, no significant reduction of VSV was observed in lungs of mice exposed to rIFNotA (1.5 x 105 U/ml). The only group in which virus was not detected in lungs was the group exposed to the higher dose of rIFNoxA/D.
Effects of exposure time. Figure 1 compares levels of VSV in lungs of mice exposed to small-particle aerosols of 5,100 6.2 ± 0.6 >0.05 a All mice were inoculated intranasally with approximately 100 PFU of VSV 20 h after ceasing aerosolization. One day after virus inoculation these mice were killed, and their lungs were assessed for virus titers. bEstimated dosage is the respiratory volume of mice per min [5] x (60 min) x (4 h) x (estimated retention volume [22] ) x (reservoir concentration of interferon) x (output coefficient of the aerosol generator); e.g., for MoIFN above: 25 cm3/min x 60 min x 4 h x 0.5 x 5,000 U/cm3 x (1 x 10-5) = 150 U. respectively. Significant decreases in virus levels were observed in mice exposed to rIFNaA for 8 h, but there were no significant decreases in lung virus titers in mice exposed to rIFNaA for 2 or 4 h compared with pulmonary titers in the saline control group (Fig. 1) . In the saline control mice, VSV levels in the lungs peaked on day 1 after inoculation (GMT, 6.; logl0/lung) and then decreased until day 4, when only very low levels of virus were detected. This pattern of' replication in saline control mice was typical of the pattern observed in numerous experiments and was virtually identical to the growth kinetics observed in infected, untreated controls (data not shown).
Virus was not detected in lungs of mice exposed to 4 . The virus GMTs for the groups exposed to rIFNaA/D or MoIFN were significantly lower than the GMTs of the virus-infected, salineexposed group on days 1 through 3 (P < 0.01) when GMTs were compared with Student's t test. No significant differences were observed between the GMTs for the saline control and the group exposed to rIFNaA on any day of observation. Similarly the interferon GMTs were significantly lower (P < 0.01) on days 1 through 3 compared with values for control mice only in the groups exposed to rIFNaA/D and MoIFN.
rIFNaA/D for 8 h and was found only on day 1 at significantly reduced levels in the group exposed to aerosols of this recombinant interferon for 4 h (Fig. 1) . No differences in virus titers were observed in the lungs of mice exposed for 2 h to rIFNaA/D aerosols and saline-treated controls (all P values were >0.05).
Similarly (Fig. 1) , no reductions in virus titers were observed in lungs of mice exposed to MoIFN for 2 h. Mice exposed to MoIFN for 4 h, however, had virus isolated on days 1 and 2. Those exposed for 8 h had no virus isolated.
Endogenous lung interferon levels. Figure 2 compares virus and endogenous interferon levels in lungs of the three groups of mice exposed to the different interferons for 4 h. The levels of endogenous interferon in these lungs correlated well with the degree of VSV replication. Thus, on day 1 after virus inoculation, relatively high concentrations of endogenous interferons (GMT, 4.5 to 4.8 log2/0.05 ml of lung homogenate) were observed in lungs of mice exposed to 452 WYDE ET AL. either saline or the less active rIFNaA, whereas only minimal concentrations of endogenous interferons (GMT, 1 to 1.2 1og2/0.05 ml of lung homogenate) were detected in lungs of mice exposed for 4 h to aerosols of rIFNaA/D or MoIFN. No endogenous interferons were detected in lungs of mice exposed for 8 h to rIFNaA/D or MoIFN, and they were only found on day 1 in lungs of mice exposed to rIFNaA for 8 h (data not shown).
Exogenous lung interferon levels. Figure 3 compares levels of exogenous interferon in lungs of mice exposed to aerosols of these materials for 8 h. The levels of exogenous interferon in groups of mice exposed for 2 or 4 h (data not shown) had kinetics up until 2 or 4 h, respectively, that were similar to those shown in Fig. 3 . However, no interferon was detectable in lungs from mice in either the 2-or 4-h exposure groups at the 24-h test interval (just before virus inoculation). There was no detectable antiviral activity in lung homogenates from mice exposed only to saline aerosol (Fig.  3) . In contrast, significant levels of interferon were detected in lungs of mice in all interferon groups by 1 h after starting the aerosolization. The levels of exogenous interferons rose in each group and were maximum by 4 h in the groups given either rIFNoaA or rIFNaA/D and by 8 h in the group exposed to MoIFN. Levels of exogenous interferons 24 h after the start of the aerosolizations (just before virus challenge) were low and not statistically significant from saline control values for all three interferon groups (all GMTs were l1.2 log2/ml). The values shown for MoIFN were determined in L929 cells (in MDBK cells all values were equal to 0), whereas the values shown for rIFNotA/D and aA were determined in MDBK cells; values for rIFNaoA/D in L929 cells were quite similar to the values shown, whereas values for rIFNaA in L929 cells were all equal to 0. DISCUSSION In these studies, mice exposed to small-particle aerosols containing MoIFN (Fig. 1) , but when given at the same concentrations for 4 h, MoIFN and rIFNotA/D were only partially protective and rIFN(xA was not significantly protective ( Table 1, Fig. 1 ). Moreover, in experiments not presented, we have observed that lower interferon concentrations are significantly protective only when administered for longer intervals.
In an earlier study we showed that interferon concentrations in the lungs of mice exposed continually to aerosols of interferon rose rapidly after the start of aerosolization and plateaued at levels comparable to those seen for endogenous interferons at the peak of natural influenza virus infection. In these studies the maximum levels of exogenous interferon reached (Fig. 3) were approximately twofold that observed for maximum levels exogenous interferon induced after VSV inoculation (Fig. 2) . This may have occurred because of the relatively low inoculum of VSV used in these experiments. Regardless, the data from both studies suggest that the use of higher interferon doses or longer exposure intervals may not be of further benefit. Conversely, the use of dosages of interferon near threshold levels could avoid the potential toxic effects due to the presence of excessive interferon. rIFNaA appeared to be the least potent of the three interferons tested, as indicated by pulmonary virus titers in mice given equivalent dosages of the three interferons (Table  1) , by dose-response studies (Fig. 1) , and by examining levels of endogenous interferon levels in lungs of test mice after challenge with VSV (Fig. 2); i.e., after 4-h aerosolizations and virus challenge, endogenous interferon production was greatest in the lungs of mice exposed to aerosols of saline or the less active rIFNoxA and least in animals exposed to rIFNaA/D and MoIFN for this period. These results correlated with results of in vitro tests where rIFNaA was shown to be 100-fold less effective in protecting mouse (L929) cells from VSV infection than was rIFNaA/D (16, 25) . The partial protection that was observed after the aerosolization of relatively high doses of rIFNaA for 8 h may have been due to the forcing of heterologous interferon molecules into tissue cell receptors by mass action (16) .
Both MoIFN and rIFN(xA/D showed similar activity in suppressing VSV pulmonary infection (Table 1 ) when used at equivalent concentrations and exposure periods. However, only when higher concentrations of rIFNa.A/D were used was VSV replication in lungs reduced to undectable levels. MoIFN was not tested at higher concentration because of the limited availability and excessive costs of higher-titered MoIFN. These findings point out the primary advantages of recombinant interferons: their high titer and availability.
Although the greater efficacy of 8-h aerosols over 4-h intervals could be due to the shorter interval between ceasing aerosolization and challenging with virus that occurred during the longer aerosolizations, this was not likely.
In studies not presented here, we have found that we can wait 3 days before challenging mice and still get significant protection (data not shown). At least two other groups of investigators have reported some success in using aerosols of interferon to reduce pulmonary virus infection (3, 21) . In the first study (3), variable but overall significant reduction of rhinovirus replication in human volunteers was observed after treatment with rIFNaA by aerosol for 1 h. In the second study (21) , some protection (-5O%) of mice from lethal influenza virus infection was achieved, but only when very specified administration regimens were utilized. With the majority of regimens used in the latter studies, the test interferon was either ineffective or appeared to cause increased mortality. In our first efficacy studies (Sun et al., in press), rIFNaA and rIFNaA/D were both effective in reducing VSV lung infection in cotton rats (rIFNoA/D was significantly more protective than rIFNaA); however, prolonged interferon treatments (23.5 h/day starting before and continuing after virus challenge) were necessary to obtain a protective effect, since neither rIFNxA or rIFNaA/D is very active in cotton rat tissues. Thus, in the present study the successful use of single treatment periods of 4 or 8 h before virug challenge represents an advance over our previous effort. The increased efficacy can be explained by the increased activities of rIFNaA and rIFNaA/D in mouse tissue cells. We did not attempt to give interferons after virus challenge since VSV replication in the lungs occurs so rapidly and is at maximum levels within 24 h after inoculation (Fig. 1) .
We have tried in numerous experiments to use MoIFN and rIFNaA/D administered as small-particle aerosols to treat avirulent and virulent influenza virus lung infections in mice. To date, despite many varied administration regimens and doses, we have not obtained any positive results. We are currently seeking the reasons for the differences seen in the VSV and influenza models, and we hope that the contrasts themselves will be informative.
